Researchers are exploring the use of whole genome and transcriptome sequencing in cancer care, including its potential for diagnosis, prognosis, and therapy. The cost and cost-effectiveness of this approach are being examined, with some studies suggesting that the full diagnostic cost may be a significant barrier to implementation. Various studies are investigating the clinical utility of whole genome sequencing in different types of cancer, including solid cancers and pediatric leukemia.